glp 1 glucagon Glucagon-like peptide-1 (GLP-1), released from the intestine, informs Regulation of GLP-1 and Glucagon
Description
Amy Sheer says shes seen some of the drawbacks of telehealth-prescribed GLP-1s in her weight management clinic at the University of Florida
Several companies have GLP-1/glucose-dependent insulinotropic polypeptide (GIP) dual agonists in phase 1 studies, including SCO-094 (Scohia Pharma), VK2735 (Viking Therapeutics) and CT-388 (Carmot Therapeutics)
There are several important limitations
These results were independent of the duration of treatment, the type of control, and the indication for GLP-1 receptor agonist treatment [13]
